Million-dollar investment from Eir Ventures will bring Swedish cancer company to clinic

Life science fund Eir Ventures leads a SEK 45m (USD 4.8m) financing round meant to bring Swedish cancer company Strike Pharma’s first drug candidate closer to human clinical trials.

Stephan Christgau (left), co-founder and partner at Eir Ventures | Photo: Nikolai Linares

Swedish biotech firm Strike Pharma has secured financial backing to further advance its antibody-based technology for the development of individualized immunotherapeutic treatments for cancer and to bring its first candidate to clinic.

This comes after the Uppsala-based company has succeeded in closing a SEK 45m (USD 4.8m) financing round, which was led by Danish-Swedish venture capital fund Eir Ventures and also saw participation from Swedish Flerie Invest.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs